Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

International Prognostic Index Model¿¡ ±Ù°ÅÇÑ Aggressive ºñÈ£ÁîŲ ¸²ÇÁÁ¾ÀÇ ¿¹ÈÄÀÎÀںм® Prognostic Factor Analysis of Aggressive Non-Hodgkin¡¯¢¥s Lymphoma Based on International Prognostic Index Model

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 6È£ p.1269 ~ 1278
¼Ò¼Ó »ó¼¼Á¤º¸
·ù¹ÎÈñ ¹Ú¿µÀÌ/±èÇбÕ/ÀÌ´ëÈ£/Á¤ÁÖ¿µ/±èµ¿¿Ï/³ªÀÓÀÏ/±èÁöÇö/À̼¼ÈÆ

Abstract

¼­·Ð
Aggressive ºñÈ£ÁîŲ ¸²ÇÁÁ¾Àº º¹ÇÕÈ­Çпä¹ýÀÇ »ç¿ëÀ¸·Î Àå±â»ýÁ¸À²ÀÌ 40¡­50% ÀÌ»óµÇ
´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖÀ¸³ª, ÀϺΠȯÀڵ鿡 À־´Â ¿¹ÈÄ°¡ ºÒ·®ÇÏ¿© ±âÁ¸ º¹ÇÕÈ­Çпä¹ýÀ¸
·Î´Â Àå±â»ýÁ¸À²À» ±â´ëÇϱ⠾î·Á¿î °ÍÀÌ »ç½ÇÀÌ´Ù. ¾ÆÁ÷ ÀÌµé ºÒ·® ¿¹Èıº¿¡ ´ëÇؼ­´Â Àû
´çÇÑ Ä¡·á¹ýÀÌ ¾ø´Â °ÍÀ¸·Î µÇ¾î ÀÖ¾î, À̵éÀÇ »ýÁ¸À²À» Çâ»ó½ÃÅ°±â À§ÇØ ½Å¾àÀ̳ª °í¿ë·®
È­Çпä¹ýÀ» ½ÃµµÇØ¾ß ÇÑ´Ù´Â ÁÖÀåÀÌ ÀÖ´Ù. ÇöÀç±îÁö ÀÌµé ºÒ·®¿¹ÈıºÀ» ±¸ºÐÇϱâ À§ÇÏ¿© ¿©
·¯ ¿¬±¸µéÀÌ ÁøÇàµÇ¾î ¿Ô´Ù. ƯÈ÷ 1993³â ¹ßÇ¥µÈ Internatioanl Prognostic Index Model¿¡¼­
´Â doxorubicin Æ÷ÇÔ º¹ÇÕÈ­Çпä¹ýÀ» ½ÃÇà¹ÞÀº 2031¸íÀÇ aggressive ºñÈ£ÁîŲ ¸²ÇÁÁ¾ ȯÀÚ
¸¦ ´ë»óÀ¸·Î ÇÏ¿© ¿¹ÈÄÀÎÀÚ¸¦ ºÐ¼®ÇÏ¿´°í, µ¶¸³¿¹ÈÄÀÎÀÚ·Î ¹àÇôÁø ¿¬·É(60¼¼ ÀÌÇÏ vs. 61¼¼
ÀÌ»ó), Ann Arbor º´±â(¥°-¥± vs. ¥²-¥³), ECOG È°µ¿µµ(0¡­1 vs. 2¡­4), ¸²ÇÁÀý¿Ü ħ¹üÀå±â
ÀÇ ¼ö(0¡­1 vs. 2 ÀÌ»ó), Ç÷û LDHÄ¡(Á¤»ó vs. Á¤»ó ÃÊ°ú)ÀÇ 5°¡Áö ¿¹ÈÄÀÎÀÚ Áß¿¡¼­ ³ª»Û
¿¹ÈÄÀÎÀÚ°¡ 0¡­1°³ ÀÖÀ» °æ¿ì ÀúÀ§Ç豺, 2°³ÀÇ °æ¿ì ÁßÀúÀ§Ç豺, 3°³ÀÇ °æ¿ì Áß°íÀ§Ç豺,
4¡­5°³ ÀÖÀ» °æ¿ì °íÀ§Ç豺À¸·Î ±¸ºÐÇÏ¿© °¢ À§Ç豺 »çÀÌ¿¡ ¿ÏÀü°üÇØÀ²°ú »ýÁ¸À²¿¡ ÇöÀúÇÑ
Â÷ÀÌ°¡ ÀÖÀ½À» º¸°íÇÏ¿´´Âµ¥, ÇöÀç ºñÈ£ÁîŲ ¸²ÇÁÁ¾ÀÇ ¿¹ÈÄ¿¹Ãø¸ðµ¨·Î¼­ ³Î¸® ¹Þ¾Æµé¿©Áö°í
ÀÖ´Â Ãß¼¼ÀÌ´Ù.
º» ¿¬±¸¿¡¼­´Â ¼­¿ï´ëÇб³º´¿øÀ» ¹æ¹®ÇÏ¿© aggressive ºñÈ£ÁîŲ ¸²ÇÁÁ¾À¸·Î Áø´Ü¹ÞÀº ȯ
ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿© ¿¹ÈÄ ÀÎÀÚ¸¦ È®ÀÎÇÏ°í ´ë»óȯÀڵ鿡¼­ International Prognostic Index
ModelÀÇ À¯¿ë¼º°ú Àû¿ë°¡´É¼ºÀ» È®ÀÎÇØ º¸°íÀÚ ÇÏ¿´´Ù.

Purpose : International Prognostic Index Model (IPIM) in aggressive non-Hodgkin¡¯s lymphoma was published and accepted generally as a better predictive model for prognosis. This study was undertaken to identify prognostic factors of aggressive
non-Hodgkin¡¯s lymphoma and usefulness of IPIM in Korea.

Materials and Methods : Previously untreated, pathologically proven 226 aggressive non-Hodgkin¡¯s lymphoma patients who were treated with CHOP or COP-BLAM V between 1986 and 1995 in Seoul National University Hospital were evaluated for clinical features predictive of overall survival.

Results : Complete response (CR) was reached in 76% of all patients. With a median follow-up of 62 months, 5-year disease free survival of complete reponders was 67% and 5-year overall survival of all patients was 54%. In a univriate analysis, age, ECOG performance status, Ann Arbor stage, histologic subtype, bone marrow involvement,
bulkiness, serum LDH level and number of extranodal involvement were significant
prognostic factors for CR and survival (p<0.05). Of these, by multivariate analysis, age
(RR 0.4, 95% Cl 0.2¡­0.9) alone was a independent prognostic factor for CR. For disease
free survival, no independent prognostic factor was found. For overall survival, Ann
Arbor stage (RR 1.7, 95% Cl 1.1¡­2.8), age (RR 1.7, 95% Cl 1.1¡­2.6), Histologic subtype
(RR 1.7, 95% Cl 1.1¡­2.8), serum LDH level (RR 1.7, 95% Cl 1.1¡­2.6) and bone marrow
involvement (RR 1.8, 95% Cl 1.0¡­3.1) were independent prognostic factors. According to
risk group of IPIM, 5-year overall survival rate was 72% in low risk group, 46% in low
intermediate risk group, 32% in high intermediate risk group, respectively, and median
survival of high risk group was 12 months (RR 1, 2.3, 4.3, 6.4 respectively).

Conclusion : IPIM is a useful model for identifying poor prognostic groups in
aggressive non-Hodgkin¡¯s lymphoma.

Å°¿öµå

Non-Hodgkin¡¯s lymphorna; Prognostic factor;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS